[ 18 F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial

Conclusion[18F]FDG PET/CT performed 6  weeks after the start of neo-CTX can serve as an early interim biomarker for TTP and pathologic response but not for OS in pediatric patients with sarcoma.

Source: EJNMMI Research - October 15, 2020 Category: Radiology Source Type: research